Brought to you by 
Eisai buys MGI Pharma
02 Jan 2008
Executive Summary
Japan's Eisai Co. Ltd. (neurology, gastrointestinal, and oncology therapeutics) will buy MGI Pharma (cancer and acute care) for $3.3bn in cash, or $41 for each of MGI's 81mm outstanding shares (a 25% premium).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai buys MGI Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice